CA2423884A1 - Improved paclitaxel-based antitumor formulation - Google Patents
Improved paclitaxel-based antitumor formulation Download PDFInfo
- Publication number
- CA2423884A1 CA2423884A1 CA002423884A CA2423884A CA2423884A1 CA 2423884 A1 CA2423884 A1 CA 2423884A1 CA 002423884 A CA002423884 A CA 002423884A CA 2423884 A CA2423884 A CA 2423884A CA 2423884 A1 CA2423884 A1 CA 2423884A1
- Authority
- CA
- Canada
- Prior art keywords
- paclitaxel
- formulation
- sterile
- solution
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229960001592 paclitaxel Drugs 0.000 title claims abstract description 64
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title claims abstract description 64
- 229930012538 Paclitaxel Natural products 0.000 title claims abstract description 63
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 238000009472 formulation Methods 0.000 title claims abstract description 34
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 7
- 102000009027 Albumins Human genes 0.000 claims abstract description 21
- 108010088751 Albumins Proteins 0.000 claims abstract description 21
- 239000002253 acid Substances 0.000 claims abstract description 12
- 239000002105 nanoparticle Substances 0.000 claims abstract description 11
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 22
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 22
- 239000000843 powder Substances 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 239000008176 lyophilized powder Substances 0.000 claims description 8
- 239000007853 buffer solution Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000012928 buffer substance Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 42
- 239000000243 solution Substances 0.000 description 37
- 229940050528 albumin Drugs 0.000 description 19
- 239000007908 nanoemulsion Substances 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 239000008174 sterile solution Substances 0.000 description 6
- 229960001701 chloroform Drugs 0.000 description 5
- 238000000265 homogenisation Methods 0.000 description 5
- 208000036366 Sensation of pressure Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 238000002525 ultrasonication Methods 0.000 description 2
- FDQGNLOWMMVRQL-UHFFFAOYSA-N Allobarbital Chemical compound C=CCC1(CC=C)C(=O)NC(=O)NC1=O FDQGNLOWMMVRQL-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229950005434 chloropyrilene Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Abstract
Antitumor formulation based on nanoparticles of paclitaxel and human serum al-bumin as obtained by the addition of a biocompatible acid to an aqueous albumin solution before this is mixed with paclitaxel during the nanoparticle production process, the injectable solutions of this formulation having a pH between 5.4 and 5.8 and having stability and inalterability with time.
Description
IMPROVED PACLITA%EL-EASED ANTITUMOI2 F°ORMULATI011f The present invention relates to an antitumor formulation based on pacli-taxel and albumin nanoparticles able to give injectable reconstituted aqueous mixtures having high inalterability with time.
Paclitaxel is a natural substance well known in literature, with important antitumor activity. Its poor water solubility makes it difficult to administer to man, for which reason various systems have been developed to render it injectable.
Bristol Myers Squibb (BMS) have conceived and patented a composition, known by the name of TAXOLO, in which the paciitaxel is emulsified with cremo-phor which induces various side effects in the patient (Lorenz et al., Agents Action 7, 63-67 ( 1987); Weiss et al., J. Clin. Oncol. 8, 1263 ( 1990)). The BMS
formulation also involves lengthy administration times due to the dilution of the active princi-ple.
To obviate the described drawbacks, BMS have patented (EP-A-0584001, EP-A-0783885, EP-A-0783886, US 5641803, US 5670537) formulations of TAXOL~
with the same dose of paclitaxel but with other excipients able to prevent strong anaphylactic reactions. However in all cases patient administration must be ef fected very- slowly, over a period of about 3 hours.
To prevent the side effects of TAXOLO, the cremophor was replaced with human serum albumin (HSA) in view of its biocompatibility and its considerable capacity to bind to the paclitaxel (Kumar et al., Res. Comm. in Chem. Path, and Pharm., 80 (3), 337-343 (1993); Paal et al., Eur. J. Biochem. 268, 2187-2191 (2001)). The property of HSA to form microspheres containing active principles dis-solved in organic solvents insoluble in water (Kramer et al., J. Pharm. Sci.
63, 1646-1647 (1974); Grinstaff and Suslick, J. Am. Chem. Soc. 112, 7807-7809 (1990); Grinstaff and Suslick, Polym. Prepr. 32, 255-256 (1991)) has also enabled the development of systems for administering paclitaxel in higher concentrations than with TAXOLO.
Injectable nanoemulsions of paclitaxel and HSA can be obtained by known ultrasonication, high pressure homogenization and microfluidization techniques (Alleman et al., Eur. J. Pharm. Biopharm. 39 (5), 173-191 (1993)).
On the basis of these elements and by using the aforestated ultrasonication and high pressure homogenization techniques, the American company VivoRx _2_ Pharmaceuticals Inc. has developed the formulation CAPXOL~R1 containing pacli-taxel and HSA.
In US 5439686, US 5498421, US 5560933 and the corresponding WO
94/ 18954, VivoRx claims microparticles of paclitaxel and HSA prepared using ul-trasonication techniques, to give particles of mean size (MPS) < IO microns.
The preparation methods described in these patents cannot be used on an industrial scale, and moreover the microparticles thus obtained have too high an MPS, which makes them unsuitable and unusable for administration to patients.
This was well known to the said VivoRx, which then in US 5916596 and US
6096331 and in WO 98/ I4I74 and WO 99/001 I3 described and claimed sterile nanoemulsions of paclitaxel and HSA obtained by reconstituting with sterile aque-ous 0.9% NaCl solution lyophilized powders with MPS < 0.2 microns. These nanoemulsions, which are obtained using high pressure homogenization, as de-scribed in the cited patents, are stated 1:o have high stability, where the term "stability" means that the MPS is constant with time and that nanoparticle precipi-tation is absent (US 6096331, Ex. 11).
Using maximum care, the present applicants have several times reproduced the examples of the aforestated patents, in particular Examples 1, 5 and 6 of US
5916596, without ever obtaining the result specified in the examples and claimed in the patent. Having prepared the mixtures as described, then processing them with an Avestin homogenizer within the pressure range recommended in US
5916596, nanoemulsions at pH=6.7 were obtained which, when evaporated in a rotavapor as reported in the said patent, always provided nanoemulsions with MPS
of about 0.2 microns (increase of MPS > 0.02 microns after evaporation) which are poorly stable in their formulations in injectable physiological solutions (increase in MPS of about 0.05 microns and tendency to sediment in about 12 hours) and diffi-cult to filter through 0.22 microns filters for their sterilization, in contrast to that stated in the said patent, The present applicants have made the most careful attempts to effect filtra-tion with the membranes described in US 5916596, but these attempts have al-ways failed, with clogging of the filters and paclitaxel yields always < 30%, in con-trast to the 70-100% declared. Moreover the stability (evaluated in accordance with the teachings of Example 11 of US 6096331) of the products prepared by the method just described, then lyophilized and reconstituted as reported in US
5916596 and US 6096331 has never reached 24 hours (hence much less than the 72 hours declared in the patents).
The main object of tl-~e present invention is therefore to provide an antitumor formulation consisting of nanoparticles of paclitaxel and human serum albumin, which with a physiological solution enables injectable reconstituted mixtures to be formed in which said particles have a stability (in the aforestated sense) consid-erably greater than that possible in the known art, and specifically a stability ex-ceeding 24 hours.
This and further objects are attained by a formulation consisting of a lyophi-lized powder of nanoparticles of paclitaxel and human serum albumin, in which the paclitaxel is present in a quantitity between 1% and 20% and the albumin between 60% and 98%, the percentages being by weight and the mean nanoparticle size being less than 0.2 microns, characterized in that said lyophilized powder contains between 1% and 20% by weight of biocompatible salts obtained by salification of at least one biocompatible acid or due to the presence of at least one biocompatible acid buffer substance, the acid or the buffer substance being present in a quantity such that the pH of a reconstituted aqueous injectable mixture of the powder is between 5.4 and 5.8.
The presence of the salts is due to the fact that an acid buffer substance is (as chemists well know) formed by an acid and a salt thereof and that some basic groups present in albumin are salified by the acids, therefore providing a mixture having a pH lower than a typical pH of albumin, i.e. 6.79-6.89 according to Merck Index, 13th Ed. page 1519.
Experiments have shown that if use is made of an acid buffer substance (such as a mixture of citric acid and sodium citrate), the results are not so good as with the use of the acid alone (citric acid or other biocompatible acid), as far as the abovementioned stability is concerned.
Obviously, the pH of the lyophilized powder can be easily measured after water has been added to form an aqueous mixture with it. The acidic nanoparticles have been studied showing that also water is present therein: the amount of water in the powder is up to 5% (w/w), usually about 2% to 4.5% (w/w). As a conse-quence, even the above mentioned nanoparticles containing water form part of the present invention.
The invention also relates to injectable reconstituted aqueous mixtures of such formulations, in which the paclitaxel is present at a concentration between 0. l and 3 mg/ml, preferably between 0.5 and 2.5 mg/ml.
The formulations of the invention may be obtained by mixing a sterile aque ous solution of human serum albumin (HSA) with a sterile solution of paclitaxel and treating this mixture in accordance with the teachings of the aforesaid Vivorx patents, but differing from such teachings in the fact that to the aqueous HSA
so lution, before it is mixed with paclitaxel, at least one biocompatible acid or acid buffer substance is added in a quantity sufficient to bring the pH of the solution to between 5.4 and 5.8, preferably between 5.5 and 5.7.
The biocompatible acids may be chosen from the group consisting of HCl, citric acid, phosphoric acid, acetic acid, biocompatible organic and inorganic acids.
The same formulations may be obtained also by a process according to which an aqueous mixture containing paclitaxel and albumin at a temperature between 0°C and 40°C is subjected to homogenization treatment at high pressure between 9000 and 40000 psi, to give a nanoemulsion which is frozen between 20°C and -80°C and is finally lyophilized by heating at a temperature between +20°C and +35°C, wherein said aqueous mixture is obtained under sterile condi tions by dissolving said albumin in sterile water to a concentration between 2% and 3% (w/v), then adding to said albumin solution between 2% and 4% (v/v) of chloro-form and then paclitaxel in sterile powder form in a quantity between 5.40%
and 15.0%, preferably between 5.60% and 13.7%, by weight on the weight of the albu-min present in the solution, at least one biocompatible acid or acid buffer sub-stance being added to said albumin solution before adding the paclitaxel in a quantity sufficient to bring the pH of the mixture to between 5.4 and 5.8, preferably between 5.5 and 5.7.
It may be noted that the use of paclitaxel in sterile powder form in the latter process not only greatly simplifies the plant itself and the process compared with the known art and enables the time required to complete the mixing of the various components before the homogenization treatment to be considerably shortened, but also enables better final yields to be obtained and simplifies the conditions to be observed in order to obtain the desired sterile lyophilized powders.
The results obtained with the use of the formulations according to the pres-ent invention are totally unexpected and surprising, because they are in contrast to the teachings of the art which provides for the use of HSA solutions of pH
values resulting from the dilution of injectable solutions of said albumin complying with FDA specifications, hence at pH=6.9~0.5 (see Examples 1, 5 and 6 of US
5916596).
In contrast to the teachings of the known art, it has been discovered that at pH
values between 5.4 and 5.8 a stability of greater than 24 hours can be obtained for the reconstituted lyophilized products.
To clarify the understanding of the characterise=ics of the present invention, some non-limiting examples of its implementation will now be described.
Preparation of a for~nulatioaa with C1 and paclitaxel dissolved in cloro-form An injectable aqueous 25% (w/v) HSA solution in accordance with FDA
specifications (pH=6.9~0.5) is diluted to 3% (iv/v) with sterile demineralized water, the pH being corrected to 5.6 with 1M HCl which salifies some basic groups pres-ent in albumin. 40 ml of said solution, previously sterilized, are mixed with 1.2 ml of a sterile solution of paclitaxel (59.0 mg/ml) in CHCIs> after which the mixture is processed in a homogenizer (suitably sterilized) at high pressure (9000-40000 psi) until a nanoemulsion (MPS < 0.2 microns) is obtained, this being frozen to -25°C
and lyophilized for 60 hours under sterile conditions, while raising the temperature to +20°C.
The powder obtained, containing 4.25 % (w/w) of paclitaxel and 3.6 (w/w) of water, is reconstituted with an aqueous 0.9% NaCI solution to a paclitaxel concen-tration of 2 mg/ml. The formulation obtained has an MPS of 0.16 microns, pH=5.6, and a stability > 24 hours.
Equivalent results were obtained by using phosphoric acid instead of HCl.
Preparation of a forxaaaalation with citric acid and paclitaxel dissolved in cloroforan An injectable aqueous 25% (w/v) I--1SA solution in accordance with FDA
specifications (pH=6.9~0.5) is diluted to 2.5% (w/v) with sterile demineralized wa-ter, the pH being corrected to 5.5 with sterile citric acid which salifies some basic groups present in albumin. 60 ml of said solution are mixed with 1.7 ml of a sterile solution of 60.0 rng/ml of paclitaxel in CHCl3, after which the mixture is processed in a homogenizer (suitably sterilized) at high pressure (9000-40000 psi) until a nanoemulsion (MPS < 0.2 microns) is obtained, this being rapidly frozen to -40°C
and lyophilized for 55 hours under sterile conditions, ~while raising the temperature to +35°C..
The powder obtained, containing 5.2% of paclitaxel and 4.9% (w/w) of water, is reconstituted with an aqueous 0.9% NaCI solution to a paclitaxel concentration of 2 mg/ml. The formulation obtained has an MPS of 0.17 microns, pH=5.5, and a stability > 24 hours.
Preparation of a formulation with ICI arid paclitaxel dissolved in cloro-form An injectable aqueous 25% HSA solution in accordance with FDA specifications is diluted to 3% (w/v) with sterile demineralized water, the pH being corrected to 5.6 with 1M HCl which salifies some basic groups present in albumin. 60 ml of said solution, suitably sterilized, are mixed with 1.5 ml of a sterile solution of 75 mg/ml of paclitaxel in CHCIs, after which the mixture is processed in a homogenizer (suitably sterilized) at high pressure (9000-40000 psi) until a nanoemulsion (MPS <
0.2 microns) is obtained, this being frozen to -50°C and lyophilized for 50 hours under sterile conditions, while raising the temperature to +30°C.
The powder obtained, containing 4.41% of paclitalYel and 3.8% (Tu/w) of wa-ter, is reconstituted with an aqueous 0.9% NaCI solution to a paclitaxel concentra-tion of 2.5 mg/m1. The formulation obtained has an M:PS of 0.175 microns, pH=5.6, and a stability > 24 hours.
By repeating the same procedure but without adding HCl and hence working at about pH 6.5, a formulation is obtained with an MPS of 0.24 microns and a stability of about 10 hours.
Preparation of a formulation with citric acid from a paclitaxel solution An injectable aqueous 25°ro (w/v) z-iSA solution in accordance with FDA
specifications is diluted to 3°io (w/v) with sterile demineralized water, the pH being corrected to 5.4 with sterile citric acid which salifies some basic groups present in albumin.
50 ml of said solution are mimed under vigorous agitation for at least 40 minutes with 1.25 ml of a sterile solution of paclitaxel in chloroform (75 mg/ml).
The mixture is processed in a homogenizer (suitably sterilized) at high pres-sure (9000-40000 psi) until a nanoemulsion (MPS < X1.2 microns) is obtained, this being rapidly frozen to -30°C and lyophilized for 57 hours under sterile conditions, while raising the temperature to +35°C.
The powder obtained, containing 5.00% (w/w) of paclitaxel and 4.3 (w/w) of water, is reconstituted with an aqueous 0.9% NaCI solution to a paclitaxel concen-tration of 2 mg/ml. The formulation obtained has an MPS of 0.19 microns, pH=5.4, and a stability > 24 hours.
Equivalent results are obtained by using acetic acid instead of citric acid.
l0 EXAMPLE 5 Preparation of a forrnazlation with Cl and pa~;lit~~el in powder dorm An injectable aqueous 25% (w/v) HSA solution in accordance with FDA
specifications (pH=6.9~0.5) is diluted to 3% (w/v) with sterile demineralized water, the pH being corrected to a value of 5.6 with 1M HCl which salifies some basic groups present in albumin.
57 ml of said solution, previously sterilized, are mixed under vigorous stir-ring for at least 30 minutes, with 1.40 ml of sterile chloroform and with 108 mg of sterile paclitaxel (titre > 99%) in powder form.
The mixture is processed in a horraogenizer (suitably sterilized) at high pres-sure (9000-40000 psi) until a nanoemulsion (MPS < 0.2 microns) is obtained, this being rapidly frozen to -80°C and lyophilized for 55 hours under sterile conditions, v~rhile raising the temperature to +30°C.
The powder obtained, containing 4.8 3 °ro (w/w) of paclitaxel and 4%
(w/w) of water, is reconstituted with an aqueous 0.9';% NaCl solution to a paclitaxel concen-tration of 2 mg/ml. The formulation obtained has an MPS of 0.175 microns, pH=5.6, and a stability > 24 hours.
Equivalent results are obtained by using phosphoric acid instead of hydro-chloric acid.
It is important to remark that the use of sterile paclitaxel in powder form en-ables to achieve the important advantage that only one reactor is required for forming the liquid mixture containing HSA and paclitaxel with consequent reduc-tion of costs and time necessary for completing the process.
F'K A l~~ThT ~ ~
Preparation of a formulation with citric acid and paclitaxel in powder form An injectable aqueous 25% (~l/v) HSA solution in accordance with FDA
specifications is diluted to 3% (w/v) with sterile demineralized water, the pH
being corrected to a value of 5.4 with citric acid which salifies some basic groups present in albumin.
50 ml of said solution, previously sterilized, are mixed under vigorous stir-ring for at least 40 minutes, with 1.23 ml of sterile chloroform and with 98 mg of sterile paclitaxel (titre > 99%) in powder form.
The mixture is processed in a homogenizer (suitably sterilized) at high pres-sure -(9000-40000 psi) until a nanoemulsion (MPS < 0,2 microns) is obtained, this being rapidly frozen to -30°C and lyophilized for 57 hours under sterile conditions, while raising the temperature to +35°C.
The powder obtained, containing 4.80 % (w/w) of paclitaxel and 3.8% (w/w) of water, is reconstituted with an aqueous 0.9% NaCI solution to a paclitaxel con-centration of 2 mg/ml. The formulation obtained has an MPS of 0.19 microns, pH=5.4, and a stability > 24 hours.
Equivalent results are obtained by using acetic acid instead of citric acid.
Preparation of a for$nulation with sterile citric acid and paclitaxel in powder foryn.
An injectable aqueous 25% (w/v) HSA solution in accordance with FDA
specifications is diluted to 3% (w/v) with sterile demineralized water, the pH
being corrected to a value of 5.5 with sterile citric acid which salifies some basic groups present in albumin.
37 ml of said solution are mixed under vigorous stirring for at least 40 min-utes, with 0.91 ml of sterile chloroform and 71 mg of sterile paclitaxel.(titre > 99%) in powder form, after which the mixture is cooled to 5-8°C.
The mixture is processed in a homogenizer (suitably sterilized) at high pres-sure (9000-40000 psi) until a nanoemulsion (MPS < 0.2 microns) is obtained, this being rapidly frozen to -80°C and lyophilized for 58 hours under sterile conditions, while raising the temperature to +30°C.
The powder obtained, containing 4.70 % (w/w) of paclitaxel and 4.5% (w/w) of water, is reconstituted with an aqueous 0.9% NaCI solution to a paclitaxel con-,. . _g_ centration of 2 mg/ml. The formulation obtained has an MPS of 0.185 microns, pH=5.5, and a stability > 24 hours.
Preparation of a formulation containing 9.35% of paclitaxel An injectable aqueous 25% HSA solution in accordance with FDA specifications is diluted to 3% (w/v) with sterile demineralized water, the pH being corrected to 5.6 with 1M HCl which salifics some basic groups present in albumin. 60 ml of said solution, suitably sterilized, are mixed with 2.15 ml. of a sterile solution of 110 mg/ml of paclitaxel in CHC13, after which the mixture is processed in a homoge-nizer (suitably sterilized) at high pressure (9000-40000 psi) until a nanoemulsion (MPS < 0.2 microns) is obtained, this being frozen to -50°C and lyophilized for 50 hours under sterile conditions, while raising the temperature to +30°C.
The powder obtained, containing 9.36% of paclitaxel and 3.9% (w/w) of wa-ter, is reconstituted with an aqueous 0.9% NaCl solution to a paclitaxel concentra-tion of 2.5 mg/ml. The formulation obtained has an MPS of 0.1'75 microns, pH=5.6, and a stability > 24 hours.
T~'XAAlfI~T G' Q
Preparation of foranulation at pI-~ 5.5 An injectable aqueous 20% (w/v) HSA solution in accordance with FDA
specifications (pH=6.9T0.5) is diluted to 3% (w/v) with sterile demineralized water, the pH being corrected to a value of 5.5 with citric acid which salifies some basic groups present in albumin.
110 ml of said solution are mixed with 4.10 ml of sterile CHCIs and with 639 mg of sterile paclitaxel (titre > 99%) in powder form, then the mixture is processed ?5 in a high pressure homogenizer (suitably sterilized) until a nanoemulsion (MPS
about 0.2 microns) is obtained, this being filtered through a sterile filter (0.2 mi-Irons), evaporated under vacuum to remove the solvents, frozen and lyophilized under sterile conditions for 48 hours.
The powder obtained, containing 10.8 % (w/w) of paclitaxel, is reconstituted with an aqueous 0.9% NaCI solution to a paclitaxel concentration of 2 mg/ml.
The formulation obtained has an MPS of 0.15 microns and a stability > 24 hours.
Paclitaxel is a natural substance well known in literature, with important antitumor activity. Its poor water solubility makes it difficult to administer to man, for which reason various systems have been developed to render it injectable.
Bristol Myers Squibb (BMS) have conceived and patented a composition, known by the name of TAXOLO, in which the paciitaxel is emulsified with cremo-phor which induces various side effects in the patient (Lorenz et al., Agents Action 7, 63-67 ( 1987); Weiss et al., J. Clin. Oncol. 8, 1263 ( 1990)). The BMS
formulation also involves lengthy administration times due to the dilution of the active princi-ple.
To obviate the described drawbacks, BMS have patented (EP-A-0584001, EP-A-0783885, EP-A-0783886, US 5641803, US 5670537) formulations of TAXOL~
with the same dose of paclitaxel but with other excipients able to prevent strong anaphylactic reactions. However in all cases patient administration must be ef fected very- slowly, over a period of about 3 hours.
To prevent the side effects of TAXOLO, the cremophor was replaced with human serum albumin (HSA) in view of its biocompatibility and its considerable capacity to bind to the paclitaxel (Kumar et al., Res. Comm. in Chem. Path, and Pharm., 80 (3), 337-343 (1993); Paal et al., Eur. J. Biochem. 268, 2187-2191 (2001)). The property of HSA to form microspheres containing active principles dis-solved in organic solvents insoluble in water (Kramer et al., J. Pharm. Sci.
63, 1646-1647 (1974); Grinstaff and Suslick, J. Am. Chem. Soc. 112, 7807-7809 (1990); Grinstaff and Suslick, Polym. Prepr. 32, 255-256 (1991)) has also enabled the development of systems for administering paclitaxel in higher concentrations than with TAXOLO.
Injectable nanoemulsions of paclitaxel and HSA can be obtained by known ultrasonication, high pressure homogenization and microfluidization techniques (Alleman et al., Eur. J. Pharm. Biopharm. 39 (5), 173-191 (1993)).
On the basis of these elements and by using the aforestated ultrasonication and high pressure homogenization techniques, the American company VivoRx _2_ Pharmaceuticals Inc. has developed the formulation CAPXOL~R1 containing pacli-taxel and HSA.
In US 5439686, US 5498421, US 5560933 and the corresponding WO
94/ 18954, VivoRx claims microparticles of paclitaxel and HSA prepared using ul-trasonication techniques, to give particles of mean size (MPS) < IO microns.
The preparation methods described in these patents cannot be used on an industrial scale, and moreover the microparticles thus obtained have too high an MPS, which makes them unsuitable and unusable for administration to patients.
This was well known to the said VivoRx, which then in US 5916596 and US
6096331 and in WO 98/ I4I74 and WO 99/001 I3 described and claimed sterile nanoemulsions of paclitaxel and HSA obtained by reconstituting with sterile aque-ous 0.9% NaCl solution lyophilized powders with MPS < 0.2 microns. These nanoemulsions, which are obtained using high pressure homogenization, as de-scribed in the cited patents, are stated 1:o have high stability, where the term "stability" means that the MPS is constant with time and that nanoparticle precipi-tation is absent (US 6096331, Ex. 11).
Using maximum care, the present applicants have several times reproduced the examples of the aforestated patents, in particular Examples 1, 5 and 6 of US
5916596, without ever obtaining the result specified in the examples and claimed in the patent. Having prepared the mixtures as described, then processing them with an Avestin homogenizer within the pressure range recommended in US
5916596, nanoemulsions at pH=6.7 were obtained which, when evaporated in a rotavapor as reported in the said patent, always provided nanoemulsions with MPS
of about 0.2 microns (increase of MPS > 0.02 microns after evaporation) which are poorly stable in their formulations in injectable physiological solutions (increase in MPS of about 0.05 microns and tendency to sediment in about 12 hours) and diffi-cult to filter through 0.22 microns filters for their sterilization, in contrast to that stated in the said patent, The present applicants have made the most careful attempts to effect filtra-tion with the membranes described in US 5916596, but these attempts have al-ways failed, with clogging of the filters and paclitaxel yields always < 30%, in con-trast to the 70-100% declared. Moreover the stability (evaluated in accordance with the teachings of Example 11 of US 6096331) of the products prepared by the method just described, then lyophilized and reconstituted as reported in US
5916596 and US 6096331 has never reached 24 hours (hence much less than the 72 hours declared in the patents).
The main object of tl-~e present invention is therefore to provide an antitumor formulation consisting of nanoparticles of paclitaxel and human serum albumin, which with a physiological solution enables injectable reconstituted mixtures to be formed in which said particles have a stability (in the aforestated sense) consid-erably greater than that possible in the known art, and specifically a stability ex-ceeding 24 hours.
This and further objects are attained by a formulation consisting of a lyophi-lized powder of nanoparticles of paclitaxel and human serum albumin, in which the paclitaxel is present in a quantitity between 1% and 20% and the albumin between 60% and 98%, the percentages being by weight and the mean nanoparticle size being less than 0.2 microns, characterized in that said lyophilized powder contains between 1% and 20% by weight of biocompatible salts obtained by salification of at least one biocompatible acid or due to the presence of at least one biocompatible acid buffer substance, the acid or the buffer substance being present in a quantity such that the pH of a reconstituted aqueous injectable mixture of the powder is between 5.4 and 5.8.
The presence of the salts is due to the fact that an acid buffer substance is (as chemists well know) formed by an acid and a salt thereof and that some basic groups present in albumin are salified by the acids, therefore providing a mixture having a pH lower than a typical pH of albumin, i.e. 6.79-6.89 according to Merck Index, 13th Ed. page 1519.
Experiments have shown that if use is made of an acid buffer substance (such as a mixture of citric acid and sodium citrate), the results are not so good as with the use of the acid alone (citric acid or other biocompatible acid), as far as the abovementioned stability is concerned.
Obviously, the pH of the lyophilized powder can be easily measured after water has been added to form an aqueous mixture with it. The acidic nanoparticles have been studied showing that also water is present therein: the amount of water in the powder is up to 5% (w/w), usually about 2% to 4.5% (w/w). As a conse-quence, even the above mentioned nanoparticles containing water form part of the present invention.
The invention also relates to injectable reconstituted aqueous mixtures of such formulations, in which the paclitaxel is present at a concentration between 0. l and 3 mg/ml, preferably between 0.5 and 2.5 mg/ml.
The formulations of the invention may be obtained by mixing a sterile aque ous solution of human serum albumin (HSA) with a sterile solution of paclitaxel and treating this mixture in accordance with the teachings of the aforesaid Vivorx patents, but differing from such teachings in the fact that to the aqueous HSA
so lution, before it is mixed with paclitaxel, at least one biocompatible acid or acid buffer substance is added in a quantity sufficient to bring the pH of the solution to between 5.4 and 5.8, preferably between 5.5 and 5.7.
The biocompatible acids may be chosen from the group consisting of HCl, citric acid, phosphoric acid, acetic acid, biocompatible organic and inorganic acids.
The same formulations may be obtained also by a process according to which an aqueous mixture containing paclitaxel and albumin at a temperature between 0°C and 40°C is subjected to homogenization treatment at high pressure between 9000 and 40000 psi, to give a nanoemulsion which is frozen between 20°C and -80°C and is finally lyophilized by heating at a temperature between +20°C and +35°C, wherein said aqueous mixture is obtained under sterile condi tions by dissolving said albumin in sterile water to a concentration between 2% and 3% (w/v), then adding to said albumin solution between 2% and 4% (v/v) of chloro-form and then paclitaxel in sterile powder form in a quantity between 5.40%
and 15.0%, preferably between 5.60% and 13.7%, by weight on the weight of the albu-min present in the solution, at least one biocompatible acid or acid buffer sub-stance being added to said albumin solution before adding the paclitaxel in a quantity sufficient to bring the pH of the mixture to between 5.4 and 5.8, preferably between 5.5 and 5.7.
It may be noted that the use of paclitaxel in sterile powder form in the latter process not only greatly simplifies the plant itself and the process compared with the known art and enables the time required to complete the mixing of the various components before the homogenization treatment to be considerably shortened, but also enables better final yields to be obtained and simplifies the conditions to be observed in order to obtain the desired sterile lyophilized powders.
The results obtained with the use of the formulations according to the pres-ent invention are totally unexpected and surprising, because they are in contrast to the teachings of the art which provides for the use of HSA solutions of pH
values resulting from the dilution of injectable solutions of said albumin complying with FDA specifications, hence at pH=6.9~0.5 (see Examples 1, 5 and 6 of US
5916596).
In contrast to the teachings of the known art, it has been discovered that at pH
values between 5.4 and 5.8 a stability of greater than 24 hours can be obtained for the reconstituted lyophilized products.
To clarify the understanding of the characterise=ics of the present invention, some non-limiting examples of its implementation will now be described.
Preparation of a for~nulatioaa with C1 and paclitaxel dissolved in cloro-form An injectable aqueous 25% (w/v) HSA solution in accordance with FDA
specifications (pH=6.9~0.5) is diluted to 3% (iv/v) with sterile demineralized water, the pH being corrected to 5.6 with 1M HCl which salifies some basic groups pres-ent in albumin. 40 ml of said solution, previously sterilized, are mixed with 1.2 ml of a sterile solution of paclitaxel (59.0 mg/ml) in CHCIs> after which the mixture is processed in a homogenizer (suitably sterilized) at high pressure (9000-40000 psi) until a nanoemulsion (MPS < 0.2 microns) is obtained, this being frozen to -25°C
and lyophilized for 60 hours under sterile conditions, while raising the temperature to +20°C.
The powder obtained, containing 4.25 % (w/w) of paclitaxel and 3.6 (w/w) of water, is reconstituted with an aqueous 0.9% NaCI solution to a paclitaxel concen-tration of 2 mg/ml. The formulation obtained has an MPS of 0.16 microns, pH=5.6, and a stability > 24 hours.
Equivalent results were obtained by using phosphoric acid instead of HCl.
Preparation of a forxaaaalation with citric acid and paclitaxel dissolved in cloroforan An injectable aqueous 25% (w/v) I--1SA solution in accordance with FDA
specifications (pH=6.9~0.5) is diluted to 2.5% (w/v) with sterile demineralized wa-ter, the pH being corrected to 5.5 with sterile citric acid which salifies some basic groups present in albumin. 60 ml of said solution are mixed with 1.7 ml of a sterile solution of 60.0 rng/ml of paclitaxel in CHCl3, after which the mixture is processed in a homogenizer (suitably sterilized) at high pressure (9000-40000 psi) until a nanoemulsion (MPS < 0.2 microns) is obtained, this being rapidly frozen to -40°C
and lyophilized for 55 hours under sterile conditions, ~while raising the temperature to +35°C..
The powder obtained, containing 5.2% of paclitaxel and 4.9% (w/w) of water, is reconstituted with an aqueous 0.9% NaCI solution to a paclitaxel concentration of 2 mg/ml. The formulation obtained has an MPS of 0.17 microns, pH=5.5, and a stability > 24 hours.
Preparation of a formulation with ICI arid paclitaxel dissolved in cloro-form An injectable aqueous 25% HSA solution in accordance with FDA specifications is diluted to 3% (w/v) with sterile demineralized water, the pH being corrected to 5.6 with 1M HCl which salifies some basic groups present in albumin. 60 ml of said solution, suitably sterilized, are mixed with 1.5 ml of a sterile solution of 75 mg/ml of paclitaxel in CHCIs, after which the mixture is processed in a homogenizer (suitably sterilized) at high pressure (9000-40000 psi) until a nanoemulsion (MPS <
0.2 microns) is obtained, this being frozen to -50°C and lyophilized for 50 hours under sterile conditions, while raising the temperature to +30°C.
The powder obtained, containing 4.41% of paclitalYel and 3.8% (Tu/w) of wa-ter, is reconstituted with an aqueous 0.9% NaCI solution to a paclitaxel concentra-tion of 2.5 mg/m1. The formulation obtained has an M:PS of 0.175 microns, pH=5.6, and a stability > 24 hours.
By repeating the same procedure but without adding HCl and hence working at about pH 6.5, a formulation is obtained with an MPS of 0.24 microns and a stability of about 10 hours.
Preparation of a formulation with citric acid from a paclitaxel solution An injectable aqueous 25°ro (w/v) z-iSA solution in accordance with FDA
specifications is diluted to 3°io (w/v) with sterile demineralized water, the pH being corrected to 5.4 with sterile citric acid which salifies some basic groups present in albumin.
50 ml of said solution are mimed under vigorous agitation for at least 40 minutes with 1.25 ml of a sterile solution of paclitaxel in chloroform (75 mg/ml).
The mixture is processed in a homogenizer (suitably sterilized) at high pres-sure (9000-40000 psi) until a nanoemulsion (MPS < X1.2 microns) is obtained, this being rapidly frozen to -30°C and lyophilized for 57 hours under sterile conditions, while raising the temperature to +35°C.
The powder obtained, containing 5.00% (w/w) of paclitaxel and 4.3 (w/w) of water, is reconstituted with an aqueous 0.9% NaCI solution to a paclitaxel concen-tration of 2 mg/ml. The formulation obtained has an MPS of 0.19 microns, pH=5.4, and a stability > 24 hours.
Equivalent results are obtained by using acetic acid instead of citric acid.
l0 EXAMPLE 5 Preparation of a forrnazlation with Cl and pa~;lit~~el in powder dorm An injectable aqueous 25% (w/v) HSA solution in accordance with FDA
specifications (pH=6.9~0.5) is diluted to 3% (w/v) with sterile demineralized water, the pH being corrected to a value of 5.6 with 1M HCl which salifies some basic groups present in albumin.
57 ml of said solution, previously sterilized, are mixed under vigorous stir-ring for at least 30 minutes, with 1.40 ml of sterile chloroform and with 108 mg of sterile paclitaxel (titre > 99%) in powder form.
The mixture is processed in a horraogenizer (suitably sterilized) at high pres-sure (9000-40000 psi) until a nanoemulsion (MPS < 0.2 microns) is obtained, this being rapidly frozen to -80°C and lyophilized for 55 hours under sterile conditions, v~rhile raising the temperature to +30°C.
The powder obtained, containing 4.8 3 °ro (w/w) of paclitaxel and 4%
(w/w) of water, is reconstituted with an aqueous 0.9';% NaCl solution to a paclitaxel concen-tration of 2 mg/ml. The formulation obtained has an MPS of 0.175 microns, pH=5.6, and a stability > 24 hours.
Equivalent results are obtained by using phosphoric acid instead of hydro-chloric acid.
It is important to remark that the use of sterile paclitaxel in powder form en-ables to achieve the important advantage that only one reactor is required for forming the liquid mixture containing HSA and paclitaxel with consequent reduc-tion of costs and time necessary for completing the process.
F'K A l~~ThT ~ ~
Preparation of a formulation with citric acid and paclitaxel in powder form An injectable aqueous 25% (~l/v) HSA solution in accordance with FDA
specifications is diluted to 3% (w/v) with sterile demineralized water, the pH
being corrected to a value of 5.4 with citric acid which salifies some basic groups present in albumin.
50 ml of said solution, previously sterilized, are mixed under vigorous stir-ring for at least 40 minutes, with 1.23 ml of sterile chloroform and with 98 mg of sterile paclitaxel (titre > 99%) in powder form.
The mixture is processed in a homogenizer (suitably sterilized) at high pres-sure -(9000-40000 psi) until a nanoemulsion (MPS < 0,2 microns) is obtained, this being rapidly frozen to -30°C and lyophilized for 57 hours under sterile conditions, while raising the temperature to +35°C.
The powder obtained, containing 4.80 % (w/w) of paclitaxel and 3.8% (w/w) of water, is reconstituted with an aqueous 0.9% NaCI solution to a paclitaxel con-centration of 2 mg/ml. The formulation obtained has an MPS of 0.19 microns, pH=5.4, and a stability > 24 hours.
Equivalent results are obtained by using acetic acid instead of citric acid.
Preparation of a for$nulation with sterile citric acid and paclitaxel in powder foryn.
An injectable aqueous 25% (w/v) HSA solution in accordance with FDA
specifications is diluted to 3% (w/v) with sterile demineralized water, the pH
being corrected to a value of 5.5 with sterile citric acid which salifies some basic groups present in albumin.
37 ml of said solution are mixed under vigorous stirring for at least 40 min-utes, with 0.91 ml of sterile chloroform and 71 mg of sterile paclitaxel.(titre > 99%) in powder form, after which the mixture is cooled to 5-8°C.
The mixture is processed in a homogenizer (suitably sterilized) at high pres-sure (9000-40000 psi) until a nanoemulsion (MPS < 0.2 microns) is obtained, this being rapidly frozen to -80°C and lyophilized for 58 hours under sterile conditions, while raising the temperature to +30°C.
The powder obtained, containing 4.70 % (w/w) of paclitaxel and 4.5% (w/w) of water, is reconstituted with an aqueous 0.9% NaCI solution to a paclitaxel con-,. . _g_ centration of 2 mg/ml. The formulation obtained has an MPS of 0.185 microns, pH=5.5, and a stability > 24 hours.
Preparation of a formulation containing 9.35% of paclitaxel An injectable aqueous 25% HSA solution in accordance with FDA specifications is diluted to 3% (w/v) with sterile demineralized water, the pH being corrected to 5.6 with 1M HCl which salifics some basic groups present in albumin. 60 ml of said solution, suitably sterilized, are mixed with 2.15 ml. of a sterile solution of 110 mg/ml of paclitaxel in CHC13, after which the mixture is processed in a homoge-nizer (suitably sterilized) at high pressure (9000-40000 psi) until a nanoemulsion (MPS < 0.2 microns) is obtained, this being frozen to -50°C and lyophilized for 50 hours under sterile conditions, while raising the temperature to +30°C.
The powder obtained, containing 9.36% of paclitaxel and 3.9% (w/w) of wa-ter, is reconstituted with an aqueous 0.9% NaCl solution to a paclitaxel concentra-tion of 2.5 mg/ml. The formulation obtained has an MPS of 0.1'75 microns, pH=5.6, and a stability > 24 hours.
T~'XAAlfI~T G' Q
Preparation of foranulation at pI-~ 5.5 An injectable aqueous 20% (w/v) HSA solution in accordance with FDA
specifications (pH=6.9T0.5) is diluted to 3% (w/v) with sterile demineralized water, the pH being corrected to a value of 5.5 with citric acid which salifies some basic groups present in albumin.
110 ml of said solution are mixed with 4.10 ml of sterile CHCIs and with 639 mg of sterile paclitaxel (titre > 99%) in powder form, then the mixture is processed ?5 in a high pressure homogenizer (suitably sterilized) until a nanoemulsion (MPS
about 0.2 microns) is obtained, this being filtered through a sterile filter (0.2 mi-Irons), evaporated under vacuum to remove the solvents, frozen and lyophilized under sterile conditions for 48 hours.
The powder obtained, containing 10.8 % (w/w) of paclitaxel, is reconstituted with an aqueous 0.9% NaCI solution to a paclitaxel concentration of 2 mg/ml.
The formulation obtained has an MPS of 0.15 microns and a stability > 24 hours.
Claims (4)
1 An antitumor formulation consisting of a lyophilized powder of nanoparticles of paclitaxel and human serum albumin, in which the paclitaxel is present in a quantitity between 1% and 20% and the albumin between 60% and 98%, the per-centages being by weight and the mean nanoparticle size being less than 0.2 mi-crons, characterized in that said lyophilized powder contains between 1% and 20%
by weight of biocompatible salts obtained by salification of at least one bicompati-ble acid or due to the presence of at least one biocompatible acid buffer substance, the acid or the buffer substance being present in a quantity such that the pH
of a reconstituted aqueous injectable mixture of the powder is between 5.4 and 5.8.
by weight of biocompatible salts obtained by salification of at least one bicompati-ble acid or due to the presence of at least one biocompatible acid buffer substance, the acid or the buffer substance being present in a quantity such that the pH
of a reconstituted aqueous injectable mixture of the powder is between 5.4 and 5.8.
2 A formulation as claimed in claim 1, characterized in that said pH is between 5.5 and 5.7.
3 A formulation as claimed in claims 1 and 2 characterized in that said lyophi-lized powder contains up to 5% (w/w) of water.
4 A formulation according to claims 1 to 3, characterized in that, when re-constituted to form a physiological injectable mixture, it contains paclitaxel at a concentration between 0.1 and 3 mg/ml.
Injectable aqueous mixture of a formulation according to claims 1 to 4, char-acterized in that it contains paclitaxel at a concentration between 0.1 and 3 mg/ml.
6 Injectable aqueous mixture as claimed in claim 5, characterized in that pa-clitaxel is present at a concentration between 0.5 and 2.5 mg/ml.
7 Physiological injectable mixture obtainable from an antitumor formulation according to any of the preceding claims.
Injectable aqueous mixture of a formulation according to claims 1 to 4, char-acterized in that it contains paclitaxel at a concentration between 0.1 and 3 mg/ml.
6 Injectable aqueous mixture as claimed in claim 5, characterized in that pa-clitaxel is present at a concentration between 0.5 and 2.5 mg/ml.
7 Physiological injectable mixture obtainable from an antitumor formulation according to any of the preceding claims.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT2002MI000680A ITMI20020680A1 (en) | 2002-03-29 | 2002-03-29 | IMPROVED ANTI-TUMOR COMPOSITION BASED ON PACLITAXEL AND METHOD FOR ITS OBTAINING |
ITMI2002A000680 | 2002-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2423884A1 true CA2423884A1 (en) | 2003-09-29 |
Family
ID=11449618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002423884A Abandoned CA2423884A1 (en) | 2002-03-29 | 2003-03-28 | Improved paclitaxel-based antitumor formulation |
Country Status (15)
Country | Link |
---|---|
US (2) | US20030187062A1 (en) |
EP (1) | EP1348430A1 (en) |
JP (1) | JP2003300877A (en) |
KR (1) | KR20030078740A (en) |
CN (1) | CN1935121A (en) |
AU (1) | AU2003200926A1 (en) |
BR (1) | BR0300826A (en) |
CA (1) | CA2423884A1 (en) |
IL (1) | IL154761A0 (en) |
IT (1) | ITMI20020680A1 (en) |
MX (1) | MXPA03002544A (en) |
NO (1) | NO340395B1 (en) |
NZ (1) | NZ524604A (en) |
RU (1) | RU2003108822A (en) |
ZA (1) | ZA200302039B (en) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070117862A1 (en) * | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US20030133955A1 (en) * | 1993-02-22 | 2003-07-17 | American Bioscience, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US8137684B2 (en) | 1996-10-01 | 2012-03-20 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
KR100789008B1 (en) * | 1997-06-27 | 2007-12-26 | 아브락시스 바이오사이언스 인크. | Novel Formulations of Pharmacological Agents |
US8853260B2 (en) * | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
EP1461056A4 (en) * | 2001-11-26 | 2006-01-25 | Supergen Inc | Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions |
DK1530465T4 (en) * | 2002-06-26 | 2016-03-21 | Medigene Ag | A method of producing a cationic liposomal preparation comprising a lipophilic compound. |
DK1585548T3 (en) | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
ES2325506T3 (en) | 2003-12-12 | 2009-09-07 | Quiral Quimica Do Brasil | PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL ACTIVE PRINCIPLES (API) ANHYDRATES AND HYDRATES; STABLE PHARMACEUTICAL COMPOSITIONS PREPARED FROM THE SAME AND USES OF SUCH COMPOSITIONS. |
US7989490B2 (en) | 2004-06-02 | 2011-08-02 | Cordis Corporation | Injectable formulations of taxanes for cad treatment |
US8003122B2 (en) * | 2004-03-31 | 2011-08-23 | Cordis Corporation | Device for local and/or regional delivery employing liquid formulations of therapeutic agents |
US8735394B2 (en) * | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
MX339142B (en) | 2005-02-18 | 2016-05-13 | Abraxis Bioscience Llc | Combinations and modes of administration of therapeutic agents and combination therapy. |
KR101457834B1 (en) | 2005-08-31 | 2014-11-05 | 아브락시스 바이오사이언스, 엘엘씨 | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
TWI429452B (en) * | 2005-08-31 | 2014-03-11 | Abraxis Bioscience Llc | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
AR054215A1 (en) | 2006-01-20 | 2007-06-13 | Eriochem Sa | A PHARMACEUTICAL FORMULATION OF A TAXANE, A SOLID COMPOSITION OF A LIOFILIZED TAXAN FROM AN ACETIC ACID SOLUTION, A PROCEDURE FOR THE PREPARATION OF A SOLID COMPOSITION OF A TAXANE, A SOLUBILIZING COMPOSITION OF A LIOFILIZED TAXANE AND AN ELEMENTARY KIT |
US20080280987A1 (en) * | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
JP2008260705A (en) * | 2007-04-11 | 2008-10-30 | Fujifilm Corp | Composition for injection |
AR063111A1 (en) | 2007-10-03 | 2008-12-30 | Eriochem Sa | A PHARMACEUTICAL FORMULATION OF TAXANO |
US8865222B2 (en) | 2008-02-11 | 2014-10-21 | Technion Research And Development Foundation Ltd. | Beta-casein assemblies for enrichment of food and beverages and methods of preparation thereof |
US8871276B2 (en) | 2008-02-11 | 2014-10-28 | Technion Research And Development Foundation Ltd. | Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents |
WO2009101613A1 (en) | 2008-02-11 | 2009-08-20 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents |
US8420110B2 (en) * | 2008-03-31 | 2013-04-16 | Cordis Corporation | Drug coated expandable devices |
US8409601B2 (en) * | 2008-03-31 | 2013-04-02 | Cordis Corporation | Rapamycin coated expandable devices |
AU2009234127B2 (en) * | 2008-04-10 | 2015-04-30 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
CN101658516B (en) * | 2008-08-26 | 2011-10-05 | 齐鲁制药有限公司 | Taxol medicinal compositions and preparation method thereof |
MY175260A (en) | 2009-04-15 | 2020-06-17 | Abraxis Bioscience Llc | Prion free nanoparticle compositions and methods of making thereof |
WO2011017835A1 (en) * | 2009-08-11 | 2011-02-17 | Nanjing University | Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding |
PT2470173E (en) * | 2009-08-25 | 2016-06-15 | Abraxis Bioscience Llc | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
MX359413B (en) | 2010-03-26 | 2018-09-27 | Abraxis Bioscience Llc | Methods of treatment of hepatocellular carcinoma. |
CA3087813A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Methods of treating cancer |
NZ703047A (en) | 2010-03-29 | 2016-11-25 | Abraxis Bioscience Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
NZ604031A (en) | 2010-06-04 | 2015-05-29 | Abraxis Bioscience Llc | Methods of treatment of pancreatic cancer |
WO2013090634A1 (en) | 2011-12-14 | 2013-06-20 | Abraxis Bioscience, Llc | Use of polymeric excipients for lyophilization or freezing of particles |
US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
MX370662B (en) | 2013-03-12 | 2019-12-19 | Abraxis Bioscience Llc | Methods of treating lung cancer. |
CA2903548A1 (en) | 2013-03-14 | 2014-09-25 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
WO2015134543A1 (en) * | 2014-03-05 | 2015-09-11 | Sorrento Therapeutics, Inc. | Pharmacokinetically equivalent nanoparticle compositions |
US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
PL3313401T3 (en) | 2015-06-29 | 2022-02-07 | Abraxis Bioscience, Llc | Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors |
CN106420665B (en) * | 2016-10-28 | 2019-04-16 | 浙江省林业科学研究院 | A kind of preparation method for the albumin nanoparticle carrier wrapping up taxone |
WO2019183146A1 (en) | 2018-03-20 | 2019-09-26 | Abraxis Bioscience, Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
SG11202100854TA (en) * | 2018-10-16 | 2021-05-28 | US Nano Food & Drug INC | Intratumor injection formulation |
AU2020375810A1 (en) | 2019-10-28 | 2022-05-12 | Abraxis Bioscience, Llc | Pharmaceutical compositions of albumin and rapamycin |
AU2021257738A1 (en) | 2020-04-13 | 2022-05-19 | US Nano Food & Drug INC | Basic chemotherapeutic intratumour injection formulation |
KR20230154864A (en) * | 2021-03-05 | 2023-11-09 | 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 | Stable docetaxel albumin nanoparticle composition |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6096331A (en) * | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
DE69433723T3 (en) * | 1993-02-22 | 2008-10-30 | Abraxis Bioscience, Inc., Los Angeles | PROCESS FOR IN VIVO ADMINISTRATION OF BIOLOGICAL SUBSTANCES AND COMPOSITIONS USED THEREFROM |
US5362478A (en) * | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US6441025B2 (en) * | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
KR100789008B1 (en) * | 1997-06-27 | 2007-12-26 | 아브락시스 바이오사이언스 인크. | Novel Formulations of Pharmacological Agents |
EP1100494A1 (en) * | 1998-07-30 | 2001-05-23 | Novopharm Biotech, Inc. | Pharmaceutically composition comprising an aqueous solution of paclitaxel and albumin |
US6350464B1 (en) * | 1999-01-11 | 2002-02-26 | Guilford Pharmaceuticals, Inc. | Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same |
CA2684454A1 (en) * | 1999-05-21 | 2000-11-18 | American Bioscience, Llc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US6482439B2 (en) * | 1999-12-29 | 2002-11-19 | Nanodelivery, Inc. | Drug delivery system exhibiting permeability control |
CN1438882A (en) * | 2000-04-10 | 2003-08-27 | 特瓦制药工业有限公司 | Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents |
ITMI20001107A1 (en) * | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | METHOD FOR TREATMENT OF SOLIC TUMORS BY INCORPORATING PACLITAXEL MICROPARTICLES OF ALBUMIN |
-
2002
- 2002-03-29 IT IT2002MI000680A patent/ITMI20020680A1/en unknown
-
2003
- 2003-03-03 EP EP03004628A patent/EP1348430A1/en not_active Withdrawn
- 2003-03-05 IL IL15476103A patent/IL154761A0/en unknown
- 2003-03-05 AU AU2003200926A patent/AU2003200926A1/en not_active Abandoned
- 2003-03-07 NZ NZ524604A patent/NZ524604A/en not_active IP Right Cessation
- 2003-03-10 US US10/383,616 patent/US20030187062A1/en not_active Abandoned
- 2003-03-13 ZA ZA200302039A patent/ZA200302039B/en unknown
- 2003-03-14 JP JP2003069884A patent/JP2003300877A/en active Pending
- 2003-03-24 MX MXPA03002544A patent/MXPA03002544A/en unknown
- 2003-03-26 BR BR0300826-6A patent/BR0300826A/en not_active Application Discontinuation
- 2003-03-28 CA CA002423884A patent/CA2423884A1/en not_active Abandoned
- 2003-03-28 RU RU2003108822/15A patent/RU2003108822A/en not_active Application Discontinuation
- 2003-03-28 CN CNA2006100912563A patent/CN1935121A/en active Pending
- 2003-03-28 KR KR10-2003-0019403A patent/KR20030078740A/en not_active Application Discontinuation
- 2003-03-28 NO NO20031447A patent/NO340395B1/en not_active IP Right Cessation
-
2006
- 2006-06-07 US US11/449,053 patent/US20070020337A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MXPA03002544A (en) | 2005-08-26 |
KR20030078740A (en) | 2003-10-08 |
AU2003200926A1 (en) | 2003-10-16 |
NO340395B1 (en) | 2017-04-10 |
ITMI20020680A1 (en) | 2003-09-29 |
US20030187062A1 (en) | 2003-10-02 |
NZ524604A (en) | 2004-03-26 |
JP2003300877A (en) | 2003-10-21 |
US20070020337A1 (en) | 2007-01-25 |
CN1935121A (en) | 2007-03-28 |
ZA200302039B (en) | 2004-03-10 |
IL154761A0 (en) | 2003-10-31 |
ITMI20020680A0 (en) | 2002-03-29 |
NO20031447L (en) | 2003-09-30 |
EP1348430A1 (en) | 2003-10-01 |
BR0300826A (en) | 2004-08-17 |
RU2003108822A (en) | 2004-11-10 |
NO20031447D0 (en) | 2003-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2423884A1 (en) | Improved paclitaxel-based antitumor formulation | |
JP4794115B2 (en) | Methods for making paclitaxel and albumin nanoparticles | |
JP4890732B2 (en) | Paclitaxel / liposome composition for cancer treatment and method for producing the same | |
KR101717672B1 (en) | Injections or eye drops, and its preparation method for producing a homogeneous solution was formed by solubilizing poorly soluble active pharmaceutical ingredient | |
JP2000501989A (en) | Stabilized nanoparticles that can be filtered under aseptic conditions | |
KR20140020289A (en) | A pharmaceutical composition for treating a disease in the oral cavity comprising rebamipide | |
WO2011047637A1 (en) | Pharmaceutical solution of taxanes comprising ph regulator and preparation method thereof | |
AU2019322287A1 (en) | Injectable pharmaceutical composition and preparation method therefor | |
EP1561460A1 (en) | Nanoparticles for the administration of active ingredients, method of producing said particles and composition containing same | |
WO2022184164A1 (en) | Stable docetaxel albumin nanoparticle composition | |
US20040126431A1 (en) | Method for preparing microspheres containing a water-soluble substance | |
EP3570819B1 (en) | Medical treatment comprising enteral administration of edaravone | |
Pathak et al. | Encapsulation of alendronate in chitosan based polymeric nanoparticles for effective management of osteoporosis–development to release kinetic study | |
CN110075073B (en) | Cabazitaxel protein nano injection and preparation method thereof | |
CN104107165B (en) | A kind of Exenatide microball preparation, preparation method and its application | |
CN107427486B (en) | Pharmaceutical compositions containing taxane-cyclodextrin complexes, methods of manufacture, and methods of use | |
CN111184692B (en) | Resveratrol preparation and preparation method thereof | |
CN113893223A (en) | Espressol omeprazole sodium freeze-dried preparation for injection and preparation method thereof | |
NAFIS et al. | Study on increasing solubility of isolates: methods and enhancement polymers | |
WO2009128357A1 (en) | Bioactive protein-containing nanoparticle composition and method for producing the same | |
CN114632059A (en) | Intravenous infusion liquid preparation containing Reidesvir and preparation method thereof | |
TWI516282B (en) | A taxane-containing drug solution containing a pH adjusting agent and a preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |